Avizakimab, formerly known as BOS161721, represents a novel therapeutic approach to treating inflammatory disorders. This monoclonal medication selectively targets interleukin-18 , a key signaling molecule https://susanuegv174546.blog-gold.com/58725998/avizakimab-a-comprehensive-analysis-into-bos161721-s-capability